Track market-moving stories before they get noisy

Gibbs Wealth Management lifted its holdings in shares of SpaceX (NASDAQ: SPCX) by 158.2% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,428 shares of the company's stock after purchasing an additional 3,938 shares during the quarter. Gibbs Wealth Management's holdings in SpaceX were

Barclays analyst Dan Levy was the latest institutional expert to revise his position toward Tesla (NASDAQ: TSLA) stock following its impressive third-quarter (Q3) earnings.

Indeed, on Monday, October 26, he replaced his previous ‘Equal Weight’ – ‘Hold’ – rating with ‘Overweight’ – ‘Buy’ – and increased his 12-month price target for TSLA shares from $370 – effectively a 0.60% drop from the latest close at $372.22 – to $450 – a 20.90% upside.

According to the Wall Street expert’s note, the change was motivated by the assessment that the potential merger between SpaceX (NASDAQ: SPCX) and Tesla could bring a premium to the car maker’s equity, but also by various business and technological developments.

Levy cited a ‘sharp inflection in Robotaxi miles driven,’ rising adoption of FSD – the company’s self-driving technology – strong energy growth, and improvements in demand as additional bullish factors.

Analysts revise Tesla (TSLA) stock price for the next 12 months Meanwhile, Barclays’ optimistic reassessment of Tesla stock was largely in line with the rating revisions the electric vehicle (EV) maker saw following the earnings though, notably, the wider outlook for TSLA remains mixed.

Overall, Wall Street views Elon Musk’s older public company as a ‘Moderate Buy’ with fourteen positive, eleven ‘Hold’, and two ‘Sell’ recommendations, per the data Finbold retrieved from TipRanks on October 26.

The average price target for Tesla stock for the next 12 months is, however, somewhat more optimistic and stands at $414.25 – 11.29% above the latest close.

Wall Street sets Tesla stock price target for the next 12 months. Source: TipRanks Additionally, the most recent ratings and forecasts came in as almost universally bullish with new share price estimates generally standing above $400. 

This trend is also visible with the analysts who still view TSLA shares as a ‘Hold’, with, for example, JPMorgan’s (NYSE: JPM) Rajat Gupta raising the estimate from $415 to $430 on October 22, and both Jefferies and CLSA opting for exactly $400 on the same day.

Tesla stock price performance Finally, despite volatility moving the equity in both directions, the recent movements ensured that Tesla stock was, at its latest close at $372.22, 4.13% in the green on the 30-day chart and 4.93% above the October 16 lows.

Tesla stock price one-month chart. Source: Google Still, despite the improving trend, TSLA remains 15.03% down year-to-date (YTD) and 17.73% in the red in the last 12 months.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.

SummaryTesla, Inc.'s growing EV backlog amid elevated fuel prices and expanding, high-margin FSD adoption underscore TSLA's near-term thesis.As the CEO feeds the Tesla - SpaceX merger exuberance, the two entities' estimated 2026 Price/Sales of 22.19x is expensive compared to NVDA (12.37x), AAPL (10.63x), and AMZN (3.23x).Regulatory/execution merger risks loom large, with a spin-off of TSLA's Chinese operations and a premium buyout price in cash/stock being likely outcomes.To deliver the "stratospheric growth," more capital and capex/cash flow pains may be necessary before the realization of the nascent robotaxi, robotics, and foundry opportunities.TSLA remains a Sell, with a prolonged/failed merger likely to trigger downside risks amid a pessimistic stock market environment. Devrimb/iStock via Getty Images

TSLA - SPCX Merger Exuberance Since my last Sell rating in July 2026, Tesla, Inc. (TSLA, TSLA:CA) has outperformed expectations by delivering a rich >20% rally against the wider market at a single-digits gain.

Part

16.31K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GOOG, NVDA, AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Tesla Inc. (NASDAQ:TSLA) gave investors a pleasant shock last week: $1.53 billion in free cash flow, or the money left over after paying for new factories and equipment.

Tesla bulls and bears have fought over the same question for two years, but one unproven catalyst is now close enough to either vindicate the optimists or expose the premium as fantasy.

Coca-Cola Co (NYSE:KO) will release its third-quarter earnings report before the opening bell on Tuesday, Oct. 27.

TB Alternative Assets Ltd. purchased a new position in Amazon.com, Inc. (NASDAQ: AMZN) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 44,700 shares of the e-commerce giant's stock, valued at approximately $11,137,000. Amazon.com accounts for 2.3% of TB Alternative Assets Ltd.'s holdings, making the stock

Pension and Wealth Management Advisors Inc. boosted its position in shares of Amazon.com, Inc. (NASDAQ: AMZN) by 50.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,519 shares of the e-commerce giant's stock after buying an additional 5,519 shares during the quarter.

Manitou Investment Management Ltd. boosted its position in shares of Microsoft Corporation (NASDAQ: MSFT) by 24.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,364 shares of the software giant's stock after purchasing an additional 30,378 shares during the

Three separate revenue engines, a dividend that keeps climbing, and a capex bill that would sink most companies. Here is why one investor keeps adding to Microsoft every quarter anyway.

I keep adding to Microsoft (NASDAQ:MSFT | MSFT Price Prediction) every quarter, and each earnings report gives me another reason to buy again.

The argument is simple: Microsoft runs three businesses that each pay their own way, so a company that can absorb a stumble anywhere is the one paying for its AI buildout. Azure supplies the growth. Microsoft 365, LinkedIn and Dynamics supply the stability. Windows and Xbox round out the mix. When one engine sputters, the others keep pulling.

Three Segments Doing the Heavy Lifting Fiscal Q4 2026 showed that support at work. Intelligent Cloud revenue reached $39.31 billion, up 32%. Productivity and Business Processes added $37.85 billion, up 14%. More Personal Computing fell 4% to $12.85 billion, and total revenue still rose 17.8% to $90.01 billion. Azure also passed $100 billion in full-year revenue for the first time.

Visibility is what decides it for me. Commercial remaining performance obligations hit $678 billion, up 84%. Nearly 90% of full-year Microsoft Cloud revenue came from customers outside the frontier model companies, so a broad base of businesses stands behind that backlog.

Receipts I Keep Rereading The first is consistency. Microsoft has beaten both EPS and revenue estimates for six straight quarters, and EPS rose from $3.46 in Q3 FY25 to $4.74 in Q4 FY26.

The second is its financial health. Interest coverage stands at 50.88x and net debt to EBITDA at 0.56. Return on equity is 34.04%, with a 46.78% operating margin.

The third is income that keeps growing. The 0.68% yield starts small, and I own it for the raises. The quarterly dividend just stepped up to $0.98 from $0.91, and full-year cash returned to shareholders exceeded $43 billion. Valuation helps too. Shares trade at a P/E of about 29 and rose only 1.59% over the past year, while fiscal 2026 net income grew 31.3%.

Why My Money Skips Amazon, Alphabet and Oracle Amazon (NASDAQ:AMZN) grew AWS 37% in Q2 2026. It also pays no dividend, trades at a P/E near 34 and reported trailing-twelve-month free cash flow of -$7.6 billion.

Alphabet (NASDAQ:GOOGL) grew Google Cloud 82%, yet it posted Q2 free cash flow of -$5.86 billion, suspended its buyback and watched long-term debt rose from $46.5 billion to $98.2 billion.

Oracle (NYSE:ORCL) grew cloud infrastructure 121%, while software revenue fell 3% and free cash flow came in at -$5.4 billion. Microsoft pays for its expansion out of $182.94 billion in fiscal 2026 operating cash flow.

Risk That Could Actually Hurt Me Capex is the risk. Fiscal 2026 spending reached $115.95 billion, up 79.6%, and Q4 free cash flow fell 23.2%. If AI demand cools, that spending turns into a drag on returns.

My thesis lasts because roughly two-thirds of capex goes to short-lived CPUs and GPUs. CFO Amy Hood said on the earnings call: “If the demand environment changes, you just slow down what is, in fact, the largest component.” Management also expects to stay free-cash-flow positive next fiscal year.

What Keeps My Buy Button Active Microsoft 365 Copilot now has over 30 million paid seats, and Satya Nadella said earlier this year, “We are only at the beginning phases of AI diffusion.” As long as three engines keep funding one growth story, I keep buying, one quarter and one raise at a time.

Contact [email protected] for any questions or corrections.

Microsoft is set to report earnings Wednesday afternoon, with traders expecting a move that could bring the stock back near its recent record.

1.49K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws.

U S Wealth Group LLC. cut its stake in shares of NVIDIA Corporation (NASDAQ: NVDA) by 7.6% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,331 shares of the computer hardware maker's stock after selling 3,655 shares during the period. NVIDIA accounts for

26.07K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of T either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor and this is not a recommendation to buy or sell a security. Investors are recommended to read all of the company's filings and press releases as well as do their own research to determine if the company fits their own investment objectives and risk portfolios.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

On October 26, 2026, we conducted a DCF analysis for Netflix Inc NFLX , which has seen a significant decline in its stock price over the past year. The current price stands at $65.85, reflecting a year-to-date drop of 29.8% and a staggering 40.9% decrease over the last year. This analysis aims to provide insights into the intrinsic value of Netflix based on various valuation models.

DCF Earnings-based intrinsic value of $94.09 vs current price of $65.85 (margin of safety: 30.0%) DCF Free Cash Flow-based intrinsic value of $83.25 (second opinion) GF Score™ of 87/100 indicates a high level of reliability for the DCF inputs What Is NFLX Worth? DCF Earnings-Based Model The DCF earnings-based model for Netflix uses a two-stage approach to estimate the intrinsic value of the stock. In the first stage, we project earnings growth over the next ten years based on the current EPS and expected growth rate. In the second stage, we calculate the terminal value based on a lower growth rate, reflecting a more stable phase of the company's life cycle.

Parameter Value Current EPS (TTM, excl. non-recurring) $3.01 10-Year Growth Rate 55.1% 10-Year Treasury Rate 4.99% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% Here’s a summary of the calculations for the two stages:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 55.1%, discounted at 11% $30.39 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $63.70 Intrinsic Value Growth + Terminal $94.09 With the current price at $65.85, the intrinsic value of $94.09 indicates that Netflix is significantly undervalued, providing a margin of safety of 30.0%. It's important to note that GuruFocus uses EPS excluding non-recurring items, as research shows stock prices correlate more closely with earnings than with free cash flow. For further details, you can access the NFLX DCF Calculator.

What Does the Free Cash Flow DCF Say? The Free Cash Flow (FCF) based intrinsic value for Netflix is calculated to be $83.25. When compared to the earnings-based intrinsic value of $94.09, both models suggest that Netflix is undervalued, albeit the FCF model indicates a more modest margin of safety of 20.9%. This alignment between the two models reinforces the view that Netflix presents a compelling investment opportunity, despite the challenges it faces.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Netflix is calculated at $104.35, providing yet another perspective on its valuation. GF Value™ is GuruFocus' proprietary measure that takes into account historical trading multiples, past business growth, and future performance estimates. All three models—the DCF earnings-based, DCF FCF-based, and GF Value™—agree that Netflix is undervalued, which adds confidence to the overall assessment. For more information, visit the GF Value™ page.

What Does NFLX's GF Score™ Tell Us? The GF Score™ evaluates a company's financial strength, profitability, growth potential, valuation, and momentum. For Netflix, the GF Score™ stands at 87/100, indicating strong fundamentals. However, the predictability rank of 1/5 stars suggests that the DCF model's reliability may be limited due to the company's volatile nature. Below is a summary of the GF Score™ metrics:

Metric Rating GF Score™ 87/100 Financial Strength 7/10 Profitability 10/10 Growth 10/10 Valuation 4/10 Momentum 2/10 For further insights, you can check the NFLX stock page.

Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to assumptions regarding growth rates and discount rates. Stocks with low predictability ratings, such as Netflix, tend to produce less reliable DCF estimates. The terminal growth rate of 4% used in this analysis is a simplifying assumption that may not reflect future realities.

What This Means for Investors In summary, all three valuation models—DCF earnings, DCF FCF, and GF Value™—point towards Netflix being undervalued at its current price. The consensus among these models, combined with the guru ownership signal indicating that 21 gurus currently hold the stock, with 12 adding and 11 trimming their positions, suggests a cautiously optimistic outlook. However, the net selling by insiders over the past 12 months raises some caution. Investors should consider these factors carefully. For a deeper dive into the DCF analysis, visit the NFLX DCF Calculator.

Frequently Asked Questions What is NFLX's intrinsic value based on DCF?

According to the analysis, the earnings-based intrinsic value is $94.09, while the FCF-based intrinsic value is $83.25.

Is NFLX overvalued or undervalued?

Both the DCF and GF Value™ models suggest that NFLX is undervalued.

How reliable is the DCF model for NFLX?

The predictability rank of 1/5 indicates that the DCF model may not be very reliable for NFLX.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

BENTONVILLE, Ark.--(BUSINESS WIRE)--Following the launch of Better Care Services earlier this year, Walmart today announced a major expansion of its Better Care Services platform with a healthcare-store experience powered by General Medicine, further expanding its marketplace of third-party providers. Combining Walmart's reach and established consumer offerings with General Medicine's purpose-built care catalog, the expanded experience brings customers more care options, a single catalog that m.

Lmcg Investments LLC decreased its stake in JPMorgan Chase and Co. (NYSE: JPM) by 1.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 132,527 shares of the financial services provider's stock after selling 1,794 shares during the quarter. JPMorgan Chase and Co.

IRON Financial LLC increased its stake in Procter and Gamble Company (The) (NYSE: PG) by 105.7% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,686 shares of the company's stock after purchasing an additional 6,519 shares during the quarter. IRON Financial LLC's

Sepio Capital LP lessened its position in shares of Johnson and Johnson (NYSE: JNJ) by 12.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,091 shares of the company's stock after selling 2,551 shares during the period. Sepio Capital LP's holdings

NBT Bank N.A. bought a new position in shares of Johnson and Johnson (NYSE: JNJ) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 102,588 shares of the company's stock, valued at approximately $27,159,000. Johnson and Johnson accounts for 1.8% of

One of these household-name S&P 500 stocks has raised its dividend every single year for seven decades, and both pay their checks from cash left over after covering every other business need. Here is what stands between them and an…

If you are at or near retirement, the dividend that matters most is the one that keeps arriving and keeps growing through recessions, lawsuits and bear markets. Chasing the biggest yield often means owning a business that strains to pay it, while durable companies whose free cash flow covers the check with room to spare can let their raises compound for decades. The two S&P 500 members below both qualify, and one of them has raised its payout for 70 consecutive years.

Johnson & Johnson
Through its Innovative Medicine and MedTech divisions, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) makes prescription drugs and medical devices. That spread across cancer drugs, immunology, neuroscience, heart devices, surgical tools and contact lenses is the source of its durability: when one product loses patent protection, dozens of others carry the load. The company now has 29 products and platforms generating at least $1 billion in annual sales, and its chief executive said on the latest earnings call that J&J is on track to "exceed $100 billion in annual revenue for the first time in our company’s 140-year history."

Dividend Safety Check for J&J
Yield: At a recent price of $265.78, the $1.34 quarterly dividend ($5.36 annualized) works out to a forward yield of about 2.02%, with a trailing yield of 1.97%. That is modest current income, but it is income that rises every year.

Coverage: Management guides to $21 billion of free cash flow this year. Paying $5.36 a share across all outstanding shares costs roughly $12.9 billion a year, or about 61% of that free cash flow. Measured against the adjusted EPS guidance midpoint of $11.10, the payout ratio is about 48%. GAAP earnings look far worse: third-quarter diluted EPS was $0.09 versus $2.12 a year ago, after roughly $7 billion in charges tied to a proposed talc settlement and two pipeline deals. That explains the trailing P/E of 40 next to a forward P/E of 21. Dividends are paid from cash, and the quarter still produced more than $6 billion of free cash flow.

Balance sheet: J&J ended the third quarter with about $17 billion of cash and marketable securities against roughly $45 billion of debt, for net debt near $28 billion. Full-year net interest expense guidance is only $150 million to $200 million, and the company’s profile notes it is one of only two U.S.-based companies with a AAA credit rating.

Track record: In April the board lifted the quarterly dividend 3.1% from $1.30 to $1.34, marking the 64th consecutive year of increases, well past the 50-year bar for Dividend King status. The payment history backs it up: the quarterly rate stepped from $1.01 in 2020 to $1.06, $1.13, $1.19, $1.24 and $1.30 in the following years before reaching today’s $1.34. The next $1.34 payment goes out December 8 to holders of record on November 24.

Why J&J Can Anchor an Income Portfolio for Decades
The growth engine is accelerating. Oncology sales grew about 17% last quarter, Tremfya rose 68.2% and Rybrevant climbed 64%, more than offsetting biosimilar losses on older drugs. Management says it sees a path to double-digit growth by the end of the decade without assuming any acquisitions. Raising the payout sits inside the company’s stated priorities, with the CFO describing capital allocation "centered on prioritizing investments that support key commercial launches, accelerate future innovation, increase our annual dividend." With a beta of 0.206, the shares have also historically moved far less than the broader market, a useful quality for a retiree who depends on stable income.

What Would Break the J&J Case
Talc litigation is the threat to watch. The proposed $5.5 billion ovarian talc resolution depends on participation from at least 95% of claimants. If that threshold fails and the cases drag on with larger judgments, cash that would otherwise fund future raises gets diverted to litigation, and while a dividend this well covered can absorb a lot, a long, open-ended legal bill is the scenario that would slow the streak.

Procter & Gamble
Procter & Gamble (NYSE:PG) sells the things households replace every week no matter what the economy does: Tide, Pampers, Gillette, Charmin, Dawn, Crest, Pantene, Olay and SK-II, organized into five divisions. Demand is strengthening. In the first quarter of fiscal 2027, organic sales rose 4.0%, all 10 product categories grew, and core EPS of $2.00 beat the $1.89 consensus, the sixth consecutive quarter P&G exceeded expectations. The Thorne acquisition, which closed October 1, adds a health and wellness brand to the portfolio.

Dividend Safety Check for P&G
Yield: At $161.25, the $1.0885 quarterly dividend ($4.354 annualized) yields about 2.70% on a forward basis, with a trailing yield of 2.61%.

Coverage: P&G generated $15.835 billion of free cash flow in fiscal 2026, up 12.74%, on $19.556 billion of operating cash flow. Its plan to pay over $10 billion in dividends this fiscal year equals around 63% of that free cash flow. Against the core EPS guidance midpoint of $7.00, the payout ratio is about 62%. The latest quarter shows the same buffer: $4.401 billion of free cash flow against $2.6 billion of dividends paid.

Balance sheet: Cash and equivalents reached $15.365 billion at quarter end, up 37.54% from a year earlier, with $55.337 billion of shareholders’ equity. The company is confident enough in that position to plan a combined $15 billion return to shareholders this fiscal year. In management’s words: "We expect to pay over $10 billion in dividends and to repurchase approximately $5 billion of common stock."

Track record: P&G highlights its 70th consecutive year of dividend increases and 136th consecutive year of dividend payments since incorporating in 1890. Payments confirm the steady climb, from $0.7907 a quarter in early 2021 through $0.8698, $0.9133, $0.9407, $1.0065 and $1.0568 to today’s $1.0885. The next payment arrives November 16.

Why P&G Can Keep Funding Dividend Raises for Decades
Few businesses are this woven into daily life. P&G’s scale gives it a productivity machine that funds reinvestment and the dividend at the same time: it delivered $2.8 billion of productivity savings last fiscal year. Growth is broadening, with Greater China organic sales up 8% and Europe up 4%. A beta of 0.377 reflects how little the stock tends to swing with the market, and the valuation trades at a forward P/E of 21 after the shares gained 10.14% over the past month.

What Would Break the P&G Case
A extended margin squeeze. This fiscal year’s outlook absorbs about $1.4 billion in after-tax commodity costs, and combined input costs and below-the-line items amount to roughly $1.9 billion, or 79 cents per share. Core gross margin already fell 150bps year over year. Management warned, "We expect these headwinds to increase in the next few quarters." If consumers push back on price increases for years rather than quarters, earnings would stall and the annual raises would likely shrink toward token size.

Two Dividend Kings Built for the Long Haul
Both carry balance sheets that can absorb a bad year. Johnson & Johnson and P&G pay their dividends out of roughly 60% of free cash flow and have raised their payouts for 64 and 70 straight years. Each faces a real threat, litigation for J&J and cost inflation for P&G, and each has the cash to work through it, so for a retiree building an income stream meant to outlast market cycles, these two durable, growing payers offer long records worth studying closely.

Contact [email protected] for any questions or corrections.

Ascent Wealth Partners LLC grew its position in ExxonMobil Corporation (NYSE: XOM) by 490.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,208 shares of the oil and gas company's stock after acquiring an additional 9,309 shares during the quarter. Ascent

Garrett Wealth Advisory Group LLC reduced its stake in ExxonMobil Corporation (NYSE: XOM) by 7.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,165 shares of the oil and gas company's stock after selling 3,452 shares during the